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sion about a child who doesn’t 
seem critically ill. You can’t let all 
the what-ifs terrorize you, or you 
would do a lumbar puncture on 
every young child with a high fever 
and do a CT scan for even the 
most minor bump on the head. So 
you just go on practicing, haunted 
by stories — stories you’re a part 
of, stories that happen to people 
you love or know well or take 
care of, stories you hear from your 
teachers and colleagues, and the 
occasional well-told story that en-
ters your brain and lives there . . . 
all those ghosts that hover at your 
shoulder or in the dark places of 
your mind. I had a peculiar sense 
of multiple levels of precepting 
— of me standing over the in-
tern, and my preceptor standing 
over me, and of the ways that your 
medical education comes down 
to you partly from people you will 
never meet.
I’d like to think of it, in part, as 
a collective medical memory. And 
also as a way of honoring the pa-
tients who have suffered “bad 
outcomes” — and their physicians, 
too, the ones who are grieving 
still, who have told and retold 
these difficult stories. Bad things 
can be only a step away, and we 
need to absorb that knowledge 
and yet still do our job. It seems 
to me right and proper that even 
in everyday primary care, there 
should arise these unexpected, 
unpredictable moments when the 
collective memory catches at your 
sleeve, when the ghosts whisper to 
you to watch out, to think again, 
or at least to scribble a cell-phone 
number on a piece of paper towel 
and call later just to be sure that 
everything’s truly okay.
No potential conflict of interest relevant 
to this article was reported.
Dr. Klass is a professor of journalism and pe-
diatrics at New York University, New York.
Copyright © 2008 Massachusetts Medical Society. 
The Moral of the Story
Exploiting a Research Underclass in Phase 1 Clinical Trials
Carl Elliott, M.D., Ph.D., and Roberto Abadie, Ph.D.
In November 1996, the Wall Street Journal reported that Eli Lilly was 
paying homeless alcoholics from a 
local shelter to participate in safety 
testing of new drugs at its trial site 
in Indianapolis.1 “These individu-
als want to help society,” asserted 
Lilly’s director of clinical pharma-
cology. The subjects, however, said 
they took part for easy money and 
free room and board. Although 
Lilly reportedly offered the lowest 
per diem in the business, it man-
aged to attract poor subjects from 
all over the country.1 The medical 
director of the local Homeless 
Initiative Program said Lilly had 
created a “shadow economy” of 
paid human subjects.
Today, the Lilly episode seems 
like an early warning about an 
emerging set of ethical problems. 
Over the past decade, clinical tri-
als have moved from universities 
to private testing sites, the pres-
sure to recruit subjects quickly has 
intensified, and ethical oversight 
has been outsourced to for-profit 
institutional review boards (IRBs). 
Payment to subjects has escalated, 
creating “shadow economies” in 
cities throughout North America 
and elsewhere. In 2005, Bloom-
berg Markets reported that SFBC 
International, a contract research 
organization, was paying immi-
grants to participate in drug trials 
under ethically questionable condi-
tions in a dilapidated Miami mo-
tel. A few months later, nine ap-
parently previously healthy subjects 
at an SFBC subsidiary in Montreal 
contracted latent tuberculosis dur-
ing a trial of an immunosuppres-
sant. In 2006, six healthy subjects 
required intensive care in a phase 
1 trial of a monoclonal antibody at 
a London facility run by the con-
tract research organization Parexel. 
For all the ethical debate over these 
cases, however, few commenta-
tors have addressed the most 
troubling question: Is it ethically 
problematic to pay poor people 
to test the safety of new drugs?
Paying study subjects is not a 
new practice, but neither is it un-
controversial. According to reg-
ulators, payment should not be 
so high as to become an “undue 
inducement,” lest subjects enroll 
in risky, unpleasant, or degrading 
trials against their better judg-
ment. But this standard gives IRBs 
little practical guidance: a sum of 
money that the wealthy can easily 
resist may be very tempting for 
poorer people. Keeping payments 
low, however, seems unfair to 
the poor, who submit to trials 
precisely because they need the 
money. And whether or not such 
people are being unduly induced, 
the larger question is whether they 
are being exploited.
To exploit people is to take un-
fair advantage of them, but there is 
no consensus that current trial ar-
rangements are unfair. Defenders 
of the status quo argue that people 
who enroll in trials have agreed to 
their conditions, that they get paid 
enough to make it worth their 
while, and that they are made bet-
ter off by the arrangement. Never-
theless, there are good reasons 
to believe that poor subjects are 
being exploited.
First, poor people are less likely 
than wealthier ones to get access 
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to the drugs in question, if and 
when they are approved. Volun-
teers are unlikely to have full-time 
employment or, therefore, to have 
health insurance. Placing the bur-
den of safety testing on the poor 
appears to contravene article 19 of 
the Declaration of Helsinki, which 
states that medical research is eth-
ically justified only if there is a 
reasonable chance that the pop-
ulation in which it is conducted 
will benefit from the results.
Second, the U.S. oversight sys-
tem is not well equipped to mon-
itor a highly competitive, market-
based, multinational research 
industry. The Office for Human 
Research Protections has no juris-
diction over privately sponsored 
studies, and the Food and Drug 
Administration inspects only about 
1% of clinical trials.2 IRBs, the 
most important bodies charged 
with protecting subjects, were de-
signed primarily to review trial de-
sign, risk–benefit ratios, and in-
formed-consent documents. Recent 
research scandals — which have 
been uncovered largely by investi-
gative reporters rather than regu-
lators — have concerned a very 
different set of issues: fraud, con-
flicts of interest, unfair payment 
practices, and unsafe or degrading 
trial conditions. Such problems are 
magnified still further when stud-
ies are conducted at private testing 
sites and reviewed by for-profit 
IRBs that are financially depen-
dent on research sponsors.
Third, even though the purpose 
of phase 1 trials is to test whether 
new drugs are safe, most sponsors 
apparently do not provide free care 
or treatment for subjects who are 
injured in these trials. In fact, no 
agency is even tracking injuries in 
phase 1 trials, much less the long-
term health of people who volun-
teer for many trials over a period of 
years. A recent study commissioned 
by the Department of Health and 
Human Services showed that only 
16% of academic health centers 
provide injured subjects with free 
care. None compensate injured 
subjects for pain and suffering or 
lost wages.3 Although no compa-
rable data are available for private 
research sponsors, there is little 
reason to believe that private spon-
sors are much more generous4; 
indeed, many include disclaimers 
in their consent forms indicating 
that subjects retain responsibility 
for their own medical care.
Most of these problems can be 
seen as consequences of the trans-
formation of clinical research into 
a business. Many subjects in phase 
1 trials today see their participa-
tion as a job.5 They must pay taxes 
on their trial income, and spon-
sors often require them to sign a 
form acknowledging their status 
as “independent contractors.” The 
payment has become high enough 
to make participating in trials 
more lucrative than holding a min-
imum-wage job, even if subjects 
abide by the requirement that they 
wait 30 days between trials. Yet 
subjects get none of the rights or 
benefits that come with a good 
job, such as workers’ compensa-
tion, the right to unionize, disabil-
ity benefits, or health insurance. 
Subjects whose livelihoods depend 
on trial income are often reluctant 
to drop out of trials that turn out 
to be risky or unpleasant, espe-
cially if they have traveled some 
distance to the trial site and have 
invested a substantial amount of 
money in accommodations while 
waiting to enter the trial. Subjects 
have little incentive to be truth-
ful about their medical history or 
health status because known med-
ical problems may preclude their 
participation in a study. Nor do 
they have anyone to go to with 
complaints. Many say they are re-
luctant to complain to sponsors 
about poor conditions for fear 
of being excluded from future tri-
als. For similar reasons, they are 
reluctant to go to a lawyer, even 
if a trial goes seriously wrong.4
Without actually intending to 
do so, policymakers have allowed 
participation in clinical trials to 
become something very close to a 
job. Sponsors call subjects’ pay-
ments “compensation” to suggest 
that they are merely reimbursing 
participants for expenses and in-
convenience, even as they fill stud-
ies with unemployed people who 
depend on trial income to make 
ends meet. They refer to paid sub-
jects as “volunteers,” implying that 
participation is a freely chosen act 
of altruism, whereas most subjects 
indicate that they take part in 
trials for the money. Regulators 
allow sponsors to use money to 
attract subjects but do not require 
them to provide the kinds of ben-
efits that subjects would demand 
if they had more power. The result 
is what one Philadelphia trial sub-
ject describes as “a mild torture 
economy.” “You are not being paid 
to do something,” he explains. 
“You are being paid to endure.”5
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